Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
CIPLA | SUN PHARMA | CIPLA/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.0 | 78.2 | 41.0% | View Chart |
P/BV | x | 4.5 | 3.3 | 135.7% | View Chart |
Dividend Yield | % | 0.5 | 0.6 | 70.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
SUN PHARMA Mar-20 |
CIPLA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 484 | 120.9% | |
Low | Rs | 357 | 315 | 113.2% | |
Sales per share (Unadj.) | Rs | 207.0 | 136.9 | 151.3% | |
Earnings per share (Unadj.) | Rs | 18.6 | 17.5 | 106.6% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 26.0 | 127.5% | |
Dividends per share (Unadj.) | Rs | 4.00 | 4.00 | 100.0% | |
Dividend yield (eoy) | % | 0.8 | 1.0 | 84.8% | |
Book value per share (Unadj.) | Rs | 195.5 | 188.7 | 103.6% | |
Shares outstanding (eoy) | m | 806.35 | 2,399.26 | 33.6% | |
Bonus/Rights/Conversions | ESOS | - | - | ||
Price / Sales ratio | x | 2.3 | 2.9 | 77.9% | |
Avg P/E ratio | x | 25.3 | 22.9 | 110.6% | |
P/CF ratio (eoy) | x | 14.2 | 15.4 | 92.4% | |
Price / Book Value ratio | x | 2.4 | 2.1 | 113.8% | |
Dividend payout | % | 21.5 | 22.9 | 93.8% | |
Avg Mkt Cap | Rs m | 379,912 | 958,864 | 39.6% | |
No. of employees | `000 | 25.8 | 17.8 | 145.5% | |
Total wages/salary | Rs m | 30,270 | 63,624 | 47.6% | |
Avg. sales/employee | Rs Th | 6,459.6 | 18,490.6 | 34.9% | |
Avg. wages/employee | Rs Th | 1,171.2 | 3,582.6 | 32.7% | |
Avg. net profit/employee | Rs Th | 580.2 | 2,357.6 | 24.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 328,375 | 50.8% | |
Other income | Rs m | 3,442 | 6,360 | 54.1% | |
Total revenues | Rs m | 170,391 | 334,735 | 50.9% | |
Gross profit | Rs m | 32,060 | 69,898 | 45.9% | |
Depreciation | Rs m | 11,747 | 20,528 | 57.2% | |
Interest | Rs m | 1,974 | 3,027 | 65.2% | |
Profit before tax | Rs m | 21,782 | 52,702 | 41.3% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,606 | 0.0% | |
Tax | Rs m | 6,312 | 8,228 | 76.7% | |
Profit after tax | Rs m | 14,995 | 41,868 | 35.8% | |
Gross profit margin | % | 19.2 | 21.3 | 90.2% | |
Effective tax rate | % | 29.0 | 15.6 | 185.6% | |
Net profit margin | % | 9.0 | 12.8 | 70.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 316,542 | 37.0% | |
Current liabilities | Rs m | 43,931 | 157,064 | 28.0% | |
Net working cap to sales | % | 43.8 | 48.6 | 90.2% | |
Current ratio | x | 2.7 | 2.0 | 132.2% | |
Inventory Days | Days | 96 | 88 | 109.3% | |
Debtors Days | Days | 85 | 105 | 81.2% | |
Net fixed assets | Rs m | 107,424 | 243,102 | 44.2% | |
Share capital | Rs m | 1,613 | 2,399 | 67.2% | |
"Free" reserves | Rs m | 156,018 | 450,245 | 34.7% | |
Net worth | Rs m | 157,630 | 452,645 | 34.8% | |
Long term debt | Rs m | 23,693 | 20,289 | 116.8% | |
Total assets | Rs m | 236,626 | 682,525 | 34.7% | |
Interest coverage | x | 12.0 | 18.4 | 65.4% | |
Debt to equity ratio | x | 0.2 | 0 | 335.3% | |
Sales to assets ratio | x | 0.7 | 0.5 | 146.6% | |
Return on assets | % | 7.2 | 6.6 | 109.0% | |
Return on equity | % | 9.5 | 9.2 | 102.8% | |
Return on capital | % | 12.8 | 11.2 | 114.3% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 74,219 | 75.5% | |
Fx outflow | Rs m | 6,764 | 27,964 | 24.2% | |
Net fx | Rs m | 49,272 | 46,255 | 106.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 65,548 | 46.8% | |
From Investments | Rs m | 1,040 | -25,888 | -4.0% | |
From Financial Activity | Rs m | -29,488 | -57,151 | 51.6% | |
Net Cashflow | Rs m | 2,340 | -13,857 | -16.9% |
Indian Promoters | % | 16.0 | 63.7 | 25.1% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 5.1 | 237.8% | |
FIIs | % | 23.7 | 23.0 | 103.0% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 8.3 | 315.7% | |
Shareholders | 161,166 | 133,026 | 121.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare CIPLA With: PFIZER GSK PHARMA PANACEA BIOTECH DR. REDDYS LAB ABBOTT INDIA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.
For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
What should you do if the market falls? In this video, I'll tell you what I will do.
A favourable demand supply scenario makes a strong case for real estate prices.
Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market
More